December 10, 2012 at 10:30
Jardin et al, ASH 2012
Related entries:
- 12/10/2012 - Jardin et al, ASH 2012
- 06/19/2013 - Jardin et al, ICML 2013
Oral communication
54th ASH Annual Meeting and Exposition (Atlanta, USA)
Session 622. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Genetics of Diffuse Large B-cell Lymphoma (#415)
Integrated Analysis of High-Resolution Gene Expression and Copy Number Profiling Identified Biallelic Deletion of CDKN2A/2B Tumor Suppressor Locus As the Most Frequent and Unique Genomic Abnormality in Diffuse Large B-Cell Lymphoma (DLBCL) with Strong Prognostic Value in Both GCB and ABC Subtypes and Not Overcome by a Dose-Intensive Immunochemotherapy Regimen Plus Rituximab. Results of a Prospective GELA Clinical Trial Program
Jardin F, Mareschal S, Figeac M, Jaïs JP, Leroy K, Copie-Bergman C, Salles GA, Coiffier B, Delarue R, Peyrade F, Bosly A, Ketterer N, Haioun C, Tilly H, Molina TJ
54th ASH Annual Meeting and Exposition (Atlanta, USA)
Session 622. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Genetics of Diffuse Large B-cell Lymphoma (#415)
Integrated Analysis of High-Resolution Gene Expression and Copy Number Profiling Identified Biallelic Deletion of CDKN2A/2B Tumor Suppressor Locus As the Most Frequent and Unique Genomic Abnormality in Diffuse Large B-Cell Lymphoma (DLBCL) with Strong Prognostic Value in Both GCB and ABC Subtypes and Not Overcome by a Dose-Intensive Immunochemotherapy Regimen Plus Rituximab. Results of a Prospective GELA Clinical Trial Program
Jardin F, Mareschal S, Figeac M, Jaïs JP, Leroy K, Copie-Bergman C, Salles GA, Coiffier B, Delarue R, Peyrade F, Bosly A, Ketterer N, Haioun C, Tilly H, Molina TJ
Abstract on ASH Confex website